Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Emergent BioSolutions
ClinicalTrials.gov Identifier:
NCT01491607
First received: December 12, 2011
Last updated: September 25, 2013
Last verified: September 2013

December 12, 2011
September 25, 2013
November 2011
May 2012   (final data collection date for primary outcome measure)
Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 63 (5 Weeks Following the Third Vaccination on Day 28). [ Time Frame: Day 63 +/- 2 days ] [ Designated as safety issue: No ]
Neutralizing antibody levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50), which is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum.
Immunogenicity as measured by anti-protective antigen (PA) antibody responses using the toxin neutralization antibody assay [ Time Frame: 100 days ] [ Designated as safety issue: No ]
Proportion of subjects acheiving a threshold response.
Complete list of historical versions of study NCT01491607 on ClinicalTrials.gov Archive Site
  • Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 70. [ Time Frame: Day 70 +/- 2 days ] [ Designated as safety issue: No ]
    Neutralizing antibody levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50), which is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum.
  • Average Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value Between Days 63 and 100 (Inclusive). [ Time Frame: Days 63 to 100 ] [ Designated as safety issue: No ]
    Neutralizing antibody levels in blinded serum samples were measured using a validated anthrax lethal toxin neutralization assay. The primary assay endpoint was the 50% neutralization factor (TNA NF50), which is calculated as the ratio of the 50% effective dose (ED50) of the test sample to the ED50 of a reference serum.
  • Incidence of Injection Site Reactions by Severity (Mild, Moderate, Severe) From Subject Diary Cards [ Time Frame: Web-enabled diaries were completed for 7 days after each of three injections (Days 0, 14, and 28). ] [ Designated as safety issue: Yes ]
    Injection site reactions (warmth, tenderness, itching, pain, arm motion limitation, redness, lump, swelling, and bruise) were evaluated by using a web-enabled subject diary. Subjects assessed the severity of warmth, tenderness, itching, pain, arm motion limitation, lump, and bruise as absent, mild, moderate, or severe based on the degree of interference with daily activities. Severity of redness and swelling were based on the diameter of the affected area. Severe injection site reactions were recorded as adverse events by the investigator site staff after confirmation with the subject.
  • Percentage of Injection Site Reactions by Severity (Mild, Moderate, Severe) From Subject Diary Cards [ Time Frame: Web-enabled diaries were completed for 7 days after each of three injections (Days 0, 14, and 28). ] [ Designated as safety issue: Yes ]
    Injection site reactions (warmth, tenderness, itching, pain, arm motion limitation, redness, lump, swelling, and bruise) were evaluated by using a web-enabled subject diary. Subjects assessed the severity of warmth, tenderness, itching, pain, arm motion limitation, lump, and bruise as absent, mild, moderate, or severe based on the degree of interference with daily activities. Severity of redness and swelling were based on the diameter of the affected area. Severe injection site reactions were recorded as adverse events by the investigator site staff after confirmation with the subject.
  • Incidence of Systemic Reactions by Severity (Mild, Moderate, Severe) From Subject Diary Cards [ Time Frame: Web-enabled diaries were completed for 7 days after each of three injections (Days 0, 14, and 28). ] [ Designated as safety issue: Yes ]
    Systemic reactions (fatigue/ tiredness, muscle ache, headache, and fever) were evaluated by using a web-enabled subject diary. Subjects assessed severity as absent, mild, moderate, or severe based on the degree of interference with daily activities. Severity of fever was assessed using a grading scale. Severe systemic reactions were to be recorded as adverse events by the investigator site staff after confirmation with the subject.
  • Percentage of Systemic Reactions by Severity (Mild, Moderate, Severe) From Subject Diary Cards [ Time Frame: Web-enabled diaries were completed for 7 days after each of three injections (Days 0, 14, and 28). ] [ Designated as safety issue: Yes ]
    Systemic reactions (fatigue/ tiredness, muscle ache, headache, and fever) were evaluated by using a web-enabled subject diary. Subjects assessed severity as absent, mild, moderate, or severe based on the degree of interference with daily activities. Severity of fever was assessed using a grading scale. Severe systemic reactions were to be recorded as adverse events by the investigator site staff after confirmation with the subject.
Immunogenicity, as defined by a predicted vaccine efficacy at defined timepoints. [ Time Frame: 100 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax. Results of this study will be used to support a post-exposure prophylaxis (PEP) indication for BioThrax.

This study will be conducted in the United States (U.S.), in 200 healthy male and female volunteer subjects ages 18 to 65 years.

The duration of study participation for each individual subject will be approximately 128 days (4.25 months), including a screening period of approximately 28 days followed by 100 days on study.

BioThrax® (also called Anthrax Vaccine Adsorbed or AVA) is the only FDA-licensed vaccine for the prevention of anthrax infection. This study will evaluate the immunogenicity of the vaccine using a post-exposure vaccination schedule. Correlations will be drawn to immunogenicity and survival data from animal models to demonstrate that BioThrax® can elicit a protective immune response for PEP.

Interventional
Phase 3
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Anthrax
Biological: BioThrax
BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
Other Name: Anthrax Vaccine Adsorbed (AVA)
Experimental: BioThrax (0.5 mL, on days 0, 14, and 28)
Intervention: Biological: BioThrax
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Be between 18 and 65 years of age, inclusive, at the time of enrollment.
  • Be in good health as determined by the investigator from medical history and a physical examination.
  • If a pre-menopausal female, must be using acceptable methods of birth control.
  • Have all hematology and chemistry parameters (measured at Screening) within the laboratory's normal range.
  • Be willing and able to return for all visits and blood collections for the duration of the study.
  • Have read, understood and signed an informed consent form.

Exclusion Criteria:

  • Prior immunization with anthrax vaccine or known exposure to anthrax organisms.
  • Intend to enlist in the military during the study.
  • Have a known allergy to aluminum hydroxide, formaldehyde, benzethonium chloride, or latex.
  • Plan to receive experimental products at any time during the study.
  • Have received a live vaccine in the 30 days before study entry.
  • Plan to receive a live vaccine at any time during the study.
  • Have ongoing drug abuse/dependence (including alcohol) issues and/or test positive in a urine drug screen for amphetamines, barbiturates, cocaine or opiates;
  • Have received immunosuppressive therapy (including systemic steroids) within 3 months prior to study entry.
  • Have a condition known to produce or be associated with immunosuppression.
  • Have received cytotoxic therapy in the previous 5 years.
  • A medical condition that, in the opinion of the Principal Investigator (PI), could adversely impact the subject's participation, safety, or conduct of the study.
Both
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01491607
EBS.AVA.006, HHSO100200700037C
No
Emergent BioSolutions
Emergent BioSolutions
Department of Health and Human Services
Principal Investigator: Robert Hopkins, MD, MPH, TM Emergent BioSolutions Inc.
Emergent BioSolutions
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP